We are live on ! Find out more
RM

RP Management Portfolio holdings

AUM $139M
1-Year Est. Return 37.98%
This Fund
S&P 500
This Quarter Est. Return
+83.1%
1 Year Est. Return
-37.98%
3 Year Est. Return
+207.8%
5 Year Est. Return
+1,098.05%
10 Year Est. Return
–
AUM
$442M
AUM Growth
+$286M
Cap. Flow
+$99M
Cap. Flow %
22.37%
Top 10 Hldgs %
100%
Holding
6
New
2
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
EPZM
Epizyme, Inc
EPZM
+$99M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 86.1%
2 Miscellaneous 13.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EPZM
1
DELISTED
Epizyme, Inc
EPZM
$164M 37.08%
+6,666,667
New +$99M
BHVN
2
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$115M 25.98%
2,111,111
– –
IMMU
3
DELISTED
Immunomedics Inc
IMMU
$92.5M 20.92%
4,373,178
– –
EPZM
4
CALL
DELISTED
Epizyme, Inc
EPZM
$61.5M 13.9%
+2,500,000
New +$37.1M
CYTK icon
5
Cytokinetics
CYTK
$10.8B
$9.29M 2.1%
875,656
– –
VIRX
6
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$44K 0.01%
3,700
– –

Similar funds

PC
Paradoxiom Capital Stamford, Connecticut $154M AUM
LA
LPF Advisors Sarasota, Florida $122M AUM 3.12% 1-Year Est. Return
TP
Thunderbird Partners London, United Kingdom $113M AUM 8.51% 1-Year Est. Return
SC
Serenity Capital Palo Alto, California $167M AUM
MADFP
Michael A Dubis Financial Planning Middleton, Wisconsin $103M AUM
RM
RCF Management Denver, Colorado $103M AUM
NC
Napatree Capital Westerly, Rhode Island $178M AUM 8.09% 1-Year Est. Return
GWA
GGM Wealth Advisors Baltimore, Maryland $180M AUM 10.57% 1-Year Est. Return

RP Management's Q4 2019 Portfolio in Review

As of Q4 2019, RP Management held 6 positions worth $442M, up 183% from $156M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

RP Management deployed $99M of net new capital in Q4 2019, opening 2 new positions. Its largest new stake was Epizyme, Inc: 6,666,667 shares worth $164M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

  • RP Management's largest Q4 2019 buy was Epizyme, Inc: 6,666,667 shares worth $164M.
  • RP Management's ten largest holdings make up 100% of its $442M portfolio in Q4 2019.
  • RP Management opened 2 new positions and closed 0 in Q4 2019.
  • RP Management's portfolio value rose 183% quarter-over-quarter to $442M.

Based on RP Management's 13F filing for Q4 2019, filed 14 Feb 2020.